SEC Form SC 13G filed by Senti Biosciences Inc.
$SNTI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2022 | $7.50 | Equal-Weight | Morgan Stanley |
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
10-Q - Senti Biosciences, Inc. (0001854270) (Filer)
Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50
Gainers CNS Pharma (NASDAQ:CNSP) stock rose 109.5% to $2.64 during Thursday's pre-market session. The company's market cap stands at $2.2 million. Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 37.23% to $1.29. The company's market cap stands at $24.3 million. Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 21.37% to $1.59. The company's market cap stands at $1.5 million. Salarius Pharmaceuticals (NASDAQ:SLRX) stock increased by 13.63% to $2.5. The market value of their outstanding shares is at $1.4 million. Absci (NASDAQ:ABSI) stock increased by 13.46% to $3.37. The company's market cap stands at $381.0 million. Traws Pharma (NASDAQ:TRAW) stock increased by 12.32% to $
Senti Biosciences Inc (NASDAQ:SNTI) shares are trading higher by 102.6% to $0.56 during Monday’s session after the company was awarded $8 million from the California Institute for Regenerative Medicines, which will support the ongoing development of SENTI-202. The company says SENTI-202 is an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025. Timothy Lu, CEO and Co-Founder of Senti Bio, expressed gratitude for CIRM’s support, highlighting SENTI-202’s potential to improve AML treatment. The trial, enr
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsLocation: New York, NYPlease click here to access the pre-recorded presentation (available September 9, 2024, at 7:00 a.m. ET)Chardan's 8th Annual Genetic Medic
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2024 and provided a summary of recent corporate and pipeline highlights. "We have demonstrated important progress year to date, dosi
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell the
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsLocation: New York, NYPlease click here to access the pre-recorded presentation (available September 9, 2024, at 7:00 a.m. ET)Chardan's 8th Annual Genetic Medic
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2024 and provided a summary of recent corporate and pipeline highlights. "We have demonstrated important progress year to date, dosi
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell the
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)